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Abstract
A number of phosphinegold(I) thiolates where, generally, the thiolate is derived from a
thionucleobase, have been screened for anti-arthritic activity in Dark Agouti rats, a gold
sensitive model for arthritis. Potency and toxicity data showed that, generally, the Ph3P
derivatives and species based on thiopurines were the most effective and that with other
complexes enhanced activity was accompanied by greater toxicity.
Introduction
Aurothiolates, such as sodium aurothiomalate (Myocrisin) and aurothioglucose (Solganol)
(Figure 1), have been used for over 70 years to treat rheumatoid arthritis (RA) and may have
potential as anti-cancer (anti-tumour) agents [1-4]. Quite surprisingly, though potent and
effective, little systematic research has been published relating anti-arthritic activity (in
experimental animals) to the chemical structure of gold(I) complexes since the development
(1971) of Auranofin ([(1-thio-13-D-glucopyranose-2,3,4,6-tetraacetato-S)(triethylphosphine)-
gold(I)], Figure 1), an orally active gold(I) complex with both thio and phosphine ligands.
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Chemical structures of some gold drugs used in the treatment of RA.
The perceived side-effects (renal, enteric, dermal), delayed action and variable bio-
availability of the currently available hydrophilic Myocrisin and lipophilic Auranofin drugs
have been viewed as a deterrent, rather than as a stimulus to search for alternative gold(I)
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(biological or synthetic) over the past 25 years, there is no anti-arthritic drug available apart
from Myocrisin which has been deemed curative (i.e. inducing remission) for RA rather than
just disease suppressant.
This report summarises some of our findings relating chemical structure, based on the P-
Au-S atomic arrangement as found in lipophilic Auranofin, to anti-arthritic activity in an
animal model. The choice of thiolate is dictated by the fact that many of the chosen
thionucleobases have biological activity themselves [e.g. 5]. Further, a number of species
reported in this contribution have proved to possess significant in vitro cytotoxicity [6,7].
Materials and methods
Synthesis
The complexes were prepared according to established procedures: 6-mercaptopurine
complexes (6-MP) [8], 6-thioguanine (6-TG)[7], 2-thiouracil (2-TU) [9], 5-carboxy-2-thiouracil
(5-CO2-TU) [9,10], 6-methyl-2-thiouracil (6-Me-2-TU)[11], 6-nPr-2-thiouracil (6-nPr-2-TU)
[12,13], 2-mercaptopyridine (2-pyS)[14], 2-mercaptopyrimidine (2-pyreS) [14], O-
Alkyldithiocarbonate (S2COR) [15-17] and [Au(SC(NPh)PPh2)2] [18]. Figure 2 shows the
chemical formulae of the thionucleobases and analogues used in this study.
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Figure 2. Chemical structure of some of the thiols used in this study.
Anti.arthritic screening
Screening for anti-arthritic activity was performed by examining the response to the gold
complexes in female dark agouti (DA) rats, a gold-sensitive rat strain [19]. DA rats were dosed
on alternate days (total doses = 7) given i.m., s.c. or p.o. as dispersions in 0.02% Tween-20-
saline or applied dermally in DMSO or DMF. Arthritis was engendered with a mycobacterial
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adjuvant injected into the tail base and expressed in all 4 paws and in tail joints after 14
days. The maximum doses were < 10 mg Au/kg. Sodium aurothiomalate (6 mg Au/kg) given
s.c. or Auranofin (6 mg Au/kg) given p.o. were used as reference complexes.
Results and Discussion
Screening protocol
The screening for anti-arthritic activity involved the inducement of an autoallergic
polyarthritis by the injection of an arthritogenic Freund’s adjuvant on day 0. Figure 3 shows
the lower parts of three animals. The one on the left is an healthy animal and the one on the
right has contracted arthritis as seen in the paw and tail swelling. The middle animal has
been treated with a gold complex: evidence for reduced inflammation can be noted from the
reduced swelling in the paws and tail, indicating the influence of the gold complex on the
arthritis. In Table ratings for both toxicity and anti-arthritic potency are given. Toxicity was
assessed by weight loss, diarrhoea and albuminuria in both normal and arthritic rats. A score
of 2+ was considered as unacceptable. Treatments completely suppressing polyarthritis on
day 18 (i.e. four days after last dose) were scored at 3+. A rating of 4+ indicated that no
arthritis had developed by d
I’*
Figure 3. Lower regions of three dark Agouti rats, from left to right: healthy animal; arthriti:
animal treated with gold drug; arthritic animal with no treatment.
Anti-arthritic activity
The results of the anti-arthritic screening for a number of phosphinegold(I) thiolate
complexes are listed in Table 1.
Several conclusions may be drawn from the experimental results present in lable I.
Clearly, several of the listed monomeric phosphinegold(I) thiolate complexes, where the
thiolate ligand is derived from a thionucleobase analogue, show cornparable if not greater
potency as well as reduced toxicity when compared to the clinically used drugs, Myocrisin
and Auranofin.
Of the complexes listed in Table I, the most active and least toxic species is [Et3PAu(6...
MP)]. Of the thiolates, the 6-mercaptopurinates (6-MP) tend to have the greater potency. It
should be noted here that 6-mercaptopurine and related thionucleobases possess anti-arthritic
activity in their own right [5] but that the addition of R3PAu leads to increased potency [8].
-[he addition of an amino substituent at C-2 in 6-MP, leading to 6-TG, generally reduces the
potency and increases the toxicity. It is of interest that in the 6-MP series of complexes, it is
the Et3P derivatives that possess the greater activity and lesser toxicity than the other R3P
analogues noting that it is Et3P that is found in Auranofin. This result contrasts that found in
subsequent series where both Ph3P and Cy3P appear to have the greater potential (see below).
Considering next the 2-thiouracilate complexes, substitution in the ring tends to increase
the potency but toxicity for these derivatives was a problem, with their administration leading
to unhealthy animals. Although not thionucleobases, some 2-mercaptopyridine and 2-
mercaptopyrimidine (2-pym) derivatives were also tested Of these, the 2-pym complex was
the more active, however, toxicity was again a problem.
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Table I: Potential therapeutic activity in ratsa
Complex Toxicity Anti-arthritic potency Ref.
1 [Et3PAu(6-MP)] 4+
2 [Ph3PAu(6-MP)] + 3+
3 [Cy3PAu(6-MP)] + 4+
4 [Et3PAu(6-TG)] + 2+
[Ph3PAu(6-TG)] 2+ 4+
6 [Cy3PAu(6-TG)] + 3+
7 [Et3PAu(2-TU)] not available 0
8 [Ph3PAu(2-TU)] not available 2+
9 [Cy3PAu(2-TU)] 2+ +
1 0 [Ph3PAu(5-CO2-2-TU)] 2+ 4+
1 1 [Cy3PAu(5-CO2-2-TU)] 0 3+
1:2 [Ph3PAu(6-Me-2-TU)] + 3+
1 3 [Ph3PAu(6-nPr-2-TU)] 2+ 4+
14 [CY3PAu(6-nPr-2-TU)] + 2+
15 [Ph3PAu(2-pyS)] + 0
16 [Ph3PAu(2-pymS)] 2+ 4+
17 [Cy3PAu(2-pymS)] 2+ 3+
Sodium aurothiomalate 2+
Auranofin 2+ 2+
[8]
[8]
[8]
[9]
[9]
a: see text for explanation of ratings
Preliminary screening was also conducted on some related phosphinegold(I) thiolates but
these were not as promising as some of the complexes tabulated in Table and, hence, full
toxicity screens were not conducted. Several phosphinegold(I) dithiocarbonates (Figure 4)
were tested. For R3PAu(S2COMe), the potency was rated as + and 3+ for R = Ph and Cy,
respectively; the R = Et complex was lethal, however, for R3PAu(S2COiPr) the ratings were 3+
and 0 for R Ph and Cy, respectively. Finally, for the dinuclear complex, [Au(SC(=N)PPh2)]2
(incorporating S- and P- donors in the one ligand, Figure 4), the potency and toxicity was
scored at + and 2+, respectively.
R3P Au--S
O
Ph2P---Au S
N //
S Au--- PPh2
Ph
R =Et, Ph, Cy
R’= Me, iPr
Figure 4. Chemical structures for R3PAu(S2COiPr) [15-17] and [Au(SC(=N)PPh2)]2 [18].
Conclusions
The biological data indicate that some of phosphinegold(I) thiolates where the thiolate is
derived from a thionucleobase, i.e. systems analogous to Auranofin, possess significant
potency against an induced arthritis in the Dark Agouti rat model. These activities rivalled
those found for both Myocrisin and Auranofin. Further, some of these derivatives were less
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toxic than the commercially available gold complexes. Structure correlations suggested that
while the most active complex contained the Et3P ligand, generally Ph3P derivatives tended
to be more active. That there is not a definitive relationship between potency/toxicity and
either the nature of the phosphine and thiolate ligand in the systems studied indicates that the
biological activity must arise from a subtle interplay between both the phosphine and thiolate
ligands.
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